AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04035304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach
Description: Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises.
Study NCT04556942 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed Bronchoscopic Lung Volume Reduction
Description: Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
Study NCT00629135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Description: Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
Study NCT00629135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Description: Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
Study NCT01711073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilization with G-CSF and Mozobil
Description: Treatment with drugs for mobilization of MSCs
Study NCT03705858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ac-Lintuzumab
Description: 225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
Study NCT04129879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ABC technique
Description: The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
Study NCT04678089 — intervention group
Intervention type: DRUG
Intervention: Bortezomib
Description: Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
Study NCT02514642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
Study NCT02514642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
Study NCT02514642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
Study NCT02514642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
Study NCT00777582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Oral single dose formulation
Study NCT01760317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline vs Parasagittal Lumbar Epidural Steroid Injection
Study NCT02730312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb14045
Description: Administered IV weekly up to 8 weeks, with or without step-up dosing
Study NCT01835041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT01835041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01835041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01835041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01835041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01835041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02713685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
Study NCT02713685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined Femoral and Sciatic nerve block
Description: Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
Study NCT00462917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleiotropic info, in-person disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session.
Study NCT00462917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AD-only info, in-person disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session.
Study NCT00462917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleiotropic info, phone disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session.
Study NCT00462917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AD-only info, phone disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session.
Study NCT02744105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
Study NCT02841501 — intervention group
Intervention type: GENETIC
Intervention: Analysis of genetic polymorphisms
Description: An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
Study NCT03543982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral probiotic product
Description: Once per day (QD), 28 days
Study NCT02467140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex ProGrib self-fixating mesh
Description: Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
Study NCT02628574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy
Description: comparison of different (ascending) doses of TRX518 monotherapy
Study NCT02628574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with gemcitabine
Description: comparison of different (ascending) doses of TRX518 in combination with gemcitabine
Study NCT02628574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with pembrolizumab
Description: comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
Study NCT02628574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518 with nivolumab
Description: comparison of different (ascending) doses of TRX518 in combination with nivolumab
Study NCT04864964 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: combined conventional and pulsed radiofrequency (CCPRF)
Description: Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
Study NCT04064099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-fitted sports mouthguard
Description: Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
Study NCT04667611 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychosocial interventions
Description: Cognitive behavioural therapy (CBT) based individual and group intervention
Study NCT03145376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: geriatric assessment
Description: 1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram.
Study NCT03425240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation
Description: Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
Study NCT00325351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477) + carboplatin
Description: Chemotherapy for recurrent ovarian cancer
Study NCT01162109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.
Study NCT01162109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc sulfate
Description: A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.
Study NCT01069692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: SBR759A 6g daily
Study NCT01069692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBR759A
Description: Placebo Comparator 0g daily
Study NCT01069692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: SBR759A 3g daily
Study NCT01069692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: 9g daily
Study NCT01069692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759A
Description: 12g daily
Study NCT01052220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP education and BP self-regulation
Description: The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done.
Study NCT01052220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Educative Nursing Intervention
Description: BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
Study NCT04447573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T
Description: Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study NCT01196754 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sevoflurane
Study NCT01921582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: * Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies).
Study NCT01921582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention
Study NCT01698606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, family-centered lifestyle intervention with behavioral counseling
Description: Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
Study NCT02467140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tack fixation
Description: Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
Study NCT00880178 — intervention group
Intervention type: DRUG
Intervention: Simvastatin and Extended-Release niacin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study NCT01698606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary, family-centered lifestyle intervention with behavioral counseling
Description: Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
Study NCT03559595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Prevent
Description: The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
Study NCT03923062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chemicalpeeling
Description: Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face.
Study NCT03923062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryopeeling
Description: Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
Study NCT03923062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: microneedling
Description: Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions
Study NCT04189874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Stool Testing
Description: Stools are tested using conventional culture techniques
Study NCT04189874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Gastrointestinal Panel
Description: Molecular-based stool assay
Study NCT01474291 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Tocilizumab administered according to prescribing information and normal clinical practice.
Study NCT02486458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Description: Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
Study NCT02486458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.23% sodium fluoride acidic gel
Description: Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
Study NCT01826305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formal Rehabilitation Therapy
Description: Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
Study NCT01826305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Independent Exercise Cohort
Description: The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
Study NCT03781050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months
Study NCT00848302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
Study NCT01283061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zafirlukast
Description: Zafirlukast tablets 20 mg
Study NCT01283061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Zafirlukast tablets 20 mg
Study NCT03991455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apyx device
Description: The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
Study NCT02042742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: punicalagin and hydroxytyrosol mixture
Description: Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
Study NCT02042742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control supplement (maltodextrin)
Description: During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.